The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | First-in-human trial of an anti-BCMA ADC for R/R myeloma
Meletios Dimopoulos, MD, University of Athens School of Medicine, Athens, Greece, discusses the results of a Phase I, first-in-human dose-escalation trial (NCT03489525) of MEDI2228 in patients with relapsed/refractory (R/R) multiple myeloma. MEDI2228 is an antibody-drug conjugate of pyrrolobenzodiazepine, a DNA crosslinking agent, and a monoclonal antibody directed against B-cell maturation antigen (BCMA). Efficacy was demonstrated at all doses and a maximum tolerated dose of 0.14mg/kg every 3 weeks was established. A unique safety profile was associated with MEDI2228, including photophobia, skin rashes, and edema. Although mitigating the toxicity of MEDI2228 remains a challenge, patients who have been heavily pre-treated could benefit from the therapy. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Advisory boards: Amgen, Bristol Myers Squibb, Takeda, BeiGene, Janssen
